Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

DJ Black, KL Kunze, LC Wienkers, BE Gidal, TL Seaton, ND McDonnell, JS Evans, JE Bauwens and WF Trager

Department of Pharmacy Practice, University of Washington, Seattle 98195, USA.

Consistent with expectations based on human in vitro microsomal experiments, administration of fluconazole (400 mg/day) for 6 days to six human volunteers significantly reduced the cytochrome P450 (P450)- dependent metabolic clearance of the warfarin enantiomers. In particular, P4502C9 catalyzed 6- and 7-hydroxylation of (S)-warfarin, the pathway primarily responsible for termination of warfarin's anticoagulant effect, was inhibited by approximately 70%. The change in (S)-warfarin pharmacokinetics caused by fluconazole dramatically increased the magnitude and duration of warfarin's hypoprothrombinemic effect. These observations indicate that co-administration of fluconazole and warfarin will result in a clinically significant metabolically based interaction The major P450-dependent, in vivo pathways of (R)-warfarin clearance were also strongly inhibited by fluconazole. 10-Hydroxylation, a metabolic pathway catalyzed exclusively by P4503A4, was inhibited by 45% whereas 6-, 7-, and 8- hydroxylations were inhibited by 61, 73, and 88%, respectively. The potent inhibition of the phenolic metabolites suggests that enzymes other than P4501A2 (weakly inhibited by fluconazole in vitro) are primarily responsible for the formation of these metabolites in vivo as predicted from in vitro kinetic studies. These data suggest that fluconazole can be expected to interact with any drug whose clearance is dominated by P450s 2C9, 3A4, and other as yet undefined isoforms. Overall, the results strongly support the hypothesis that metabolically based in vivo drug interactions may be predicted from human in vitro microsomal data.

Volume 24, Issue 4, pp. 422-428, 04/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. H. Wright, G. A. Herman, A. Maes, Q. Liu, A. O. Johnson-Levonas, and J. A. Wagner Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin J. Clin. Pharmacol., October 1, 2009; 49(10): 1157 - 1167. [Abstract] [Full Text] [PDF]

				V.-V. Hynninen, K. T. Olkkola, K. Leino, S. Lundgren, P. J. Neuvonen, A. Rane, M. Valtonen, H. Vyyrylainen, and K. Laine Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1967 - 1972. [Abstract] [Full Text] [PDF]

				E. V. HERSH and P. A. MOORE Drug interactions in dentistry: The importance of knowing your CYPs J Am Dent Assoc, March 1, 2004; 135(3): 298 - 311. [Abstract] [Full Text] [PDF]

				G. Scott, L. Yih, C.-M. Yeh, S. Milosavljev, A. Laurent, and C. Rordorf Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects J. Clin. Pharmacol., February 1, 2004; 44(2): 193 - 199. [Abstract] [Full Text] [PDF]

				J. M. Neal, K. L. Kunze, R. H. Levy, R. A. O'Reilly, and W. F. Trager KIIV, AN IN VIVO PARAMETER FOR PREDICTING THE MAGNITUDE OF A DRUG INTERACTION ARISING FROM COMPETITIVE ENZYME INHIBITION Drug Metab. Dispos., August 1, 2003; 31(8): 1043 - 1048. [Abstract] [Full Text] [PDF]

				P. R. Gentry, C. E. Hack, L. Haber, A. Maier, and H. J. Clewell III An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion Toxicol. Sci., November 1, 2002; 70(1): 120 - 139. [Abstract] [Full Text] [PDF]

				W. Zhang, Y. Ramamoorthy, T. Kilicarslan, H. Nolte, R. F. Tyndale, and E. M. Sellers Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives Drug Metab. Dispos., March 1, 2002; 30(3): 314 - 318. [Abstract] [Full Text] [PDF]

				J. S. Ngui, Q. Chen, M. Shou, R. W. Wang, R. A. Stearns, T. A. Baillie, and W. Tang In Vitro Stimulation of Warfarin Metabolism by Quinidine: Increases in the Formation of 4'- and 10-Hydroxywarfarin Drug Metab. Dispos., June 1, 2001; 29(6): 877 - 886. [Abstract] [Full Text]

				R. L. Voorman, N. A. Payne, L. C. Wienkers, M. J. Hauer, and P. E. Sanders Interaction of Delavirdine with Human Liver Microsomal Cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6 Drug Metab. Dispos., January 1, 2001; 29(1): 41 - 47. [Abstract] [Full Text]

				J.-W. Ko, Z. Desta, and D. A. Flockhart Human N-Demethylation of (S)-Mephenytoin by Cytochrome P450s 2C9 and 2B6 Drug Metab. Dispos., August 1, 1998; 26(8): 775 - 778. [Abstract] [Full Text]